Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 69901 KiB)
Schipper, L.J.; Monkhorst, K.; Samsom, K.G.; Bosch, L.J.W.; Snaebjornsson, P.; van Boven, H.; Roepman, P.; van der Kolk, L.E.; van Houdt, W.J.; van der Graaf, W.T.A.; Meijer, G.A.; Voest, E.E. Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients. Cancers 2022, 14, 436. https://doi.org/10.3390/cancers14020436
Schipper LJ, Monkhorst K, Samsom KG, Bosch LJW, Snaebjornsson P, van Boven H, Roepman P, van der Kolk LE, van Houdt WJ, van der Graaf WTA, Meijer GA, Voest EE. Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients. Cancers. 2022; 14(2):436. https://doi.org/10.3390/cancers14020436
Chicago/Turabian StyleSchipper, Luuk J., Kim Monkhorst, Kris G. Samsom, Linda J.W. Bosch, Petur Snaebjornsson, Hester van Boven, Paul Roepman, Lizet E. van der Kolk, Winan J. van Houdt, Winette T.A. van der Graaf, Gerrit A. Meijer, and Emile E. Voest. 2022. "Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients" Cancers 14, no. 2: 436. https://doi.org/10.3390/cancers14020436